City of Hope Developes CAR-T Cell Therapy in Ovarian Cancer"City of Hope's research helped develop CAR T cell therapies for blood cancers, and these patients are now seeing long-term benefits from the therapy, but we can't stop there," said Saul Priceman, Ph.D., associate professor in the Department of Hematology & Hematopoietic Cell Transplantation and associate director of Translational Sciences & Technologies in the T Cell Therapeutics Research Laboratory at City of Hope. "The next frontier is solid tumors, and City of Hope is taking on that challenge."
Developing a CAR T cell therapy for solid tumors is particularly challenging because the therapy needs to first reach the solid tumor and then survive in a harsh microenvironment that is filled with cancer cells and other cells that prevent attack by the CAR T cells.
Priceman and his team also found that by adding the cytokine Interleukin-12 (IL-12), a protein that sends signals to the immune system, to the CAR T cell therapy.
ONCYs pelareorep is able to convert a harsh microenvironment that is filled with cancer cells and other cells that prevent attack by the CAR T cells.
https://www.biospace.com/article/releases/city-of-hope-researchers-develop-a-car-t-cell-therapy-for-advanced-ovarian-cancer/